MRK vs TSLA: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
VS
Tesla, Inc. · Consumer Cyclical
$343.23
-5.3% upside to fair value
Low Conviction
Grade D
QuantHub Verdict
MRK has more upside to fair value
(-2.9%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
TSLA |
| Current Price |
$121.42 |
$343.23 |
| Fair Value Estimate |
$118.00 |
$325.00 |
| Upside to Fair Value |
-2.9%
|
-5.3%
|
| Market Cap |
$300.2B |
$1,287.9B |
| Forward P/E |
14.0x
|
205.5x
|
| EV / EBITDA |
11.8x
|
108.8x
|
| Price / Sales |
4.1x
|
13.6x
|
| Price / FCF |
21.4x
|
207.1x
|
| Revenue Growth YoY |
+1.3%
|
-2.9%
|
| Gross Margin |
81.5%
|
18.0%
|
| Operating Margin |
41.2%
|
4.6%
|
| Return on Equity |
34.7%
|
4.8%
|
| Dividend Yield |
3.1% |
0% |
| FCF Yield |
4.7%
|
0.48%
|
| Analyst Consensus |
Buy
|
—
|
Investment Thesis
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Tesla remains the most polarizing stock in markets. The core auto business is deteriorating: FY2025 revenue fell 2.9% to $94.8B, net income dropped 46.8% to $3.8B, and Q4 deliveries declined 15.6% YoY to 418K units. Yet the stock trades at 13.6x TTM P/S (near 5yr highs) on the optionality of Cybercab robotaxis launching April 2026, FSD reaching unsupervised status in Austin, and Optimus humanoid …
Accumulation Zones
| Metric |
MRK |
TSLA |
| Zone Low |
$88.00 |
$244.00 |
| Zone High |
$100.00 |
$276.00 |
| In Buy Zone? |
No
|
No
|